Renasant (RNST) Analysts See $0.69 EPS; Agios Pharmaceuticals (AGIO) SI Decreased By 9.79%

April 10, 2018 - By Ellis Scott

Renasant Corporation (NASDAQ:RNST) Logo

Analysts expect Renasant Corporation (NASDAQ:RNST) to report $0.69 EPS on April, 24.They anticipate $0.14 EPS change or 25.45% from last quarter’s $0.55 EPS. RNST’s profit would be $34.09M giving it 15.78 P/E if the $0.69 EPS is correct. After having $0.64 EPS previously, Renasant Corporation’s analysts see 7.81% EPS growth. The stock decreased 0.46% or $0.2 during the last trading session, reaching $43.56. About 180,367 shares traded or 7.60% up from the average. Renasant Corporation (NASDAQ:RNST) has risen 7.07% since April 10, 2017 and is uptrending. It has underperformed by 4.48% the S&P500.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) had a decrease of 9.79% in short interest. AGIO’s SI was 6.07M shares in April as released by FINRA. Its down 9.79% from 6.72 million shares previously. With 1.21 million avg volume, 5 days are for Agios Pharmaceuticals Inc (NASDAQ:AGIO)’s short sellers to cover AGIO’s short positions. The SI to Agios Pharmaceuticals Inc’s float is 14.12%. The stock increased 9.26% or $6.78 during the last trading session, reaching $80. About 736,665 shares traded or 19.95% up from the average. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 41.40% since April 10, 2017 and is uptrending. It has outperformed by 29.85% the S&P500.

Since October 16, 2017, it had 1 buy, and 19 sales for $16.93 million activity. Hoerter Steven L. sold $161,192 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Thursday, February 22. Alenson Carman sold $161,250 worth of stock or 2,150 shares. Schenkein David P sold $1.05 million worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Thursday, March 1. 2,000 shares were sold by Bowden Christopher, worth $157,500 on Thursday, February 1. The insider Cantley Lewis Clayton Jr. sold 4,000 shares worth $284,380. Shares for $16,688 were bought by Scadden David. 3,000 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares with value of $228,128 were sold by Biller Scott.

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 44 analyst reports since July 23, 2015 according to SRatingsIntel. JP Morgan maintained the stock with “Overweight” rating in Thursday, February 15 report. The stock has “Buy” rating by Canaccord Genuity on Monday, June 13. The firm has “Buy” rating by Oppenheimer given on Tuesday, August 8. The firm has “Buy” rating given on Wednesday, March 30 by SunTrust. Oppenheimer maintained the stock with “Buy” rating in Tuesday, August 1 report. Canaccord Genuity maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) rating on Monday, June 5. Canaccord Genuity has “Buy” rating and $9000 target. The firm has “Hold” rating by Canaccord Genuity given on Friday, August 7. SunTrust maintained the stock with “Buy” rating in Sunday, November 19 report. Oppenheimer upgraded the stock to “Outperform” rating in Tuesday, January 17 report. TH Capital maintained it with “Neutral” rating and $75 target in Monday, November 9 report.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $4.59 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Investors sentiment increased to 1.22 in Q4 2017. Its up 0.01, from 1.21 in 2017Q3. It improved, as 19 investors sold Agios Pharmaceuticals, Inc. shares while 48 reduced holdings. 27 funds opened positions while 55 raised stakes. 45.70 million shares or 2.27% more from 44.69 million shares in 2017Q3 were reported. Loomis Sayles And Company Ltd Partnership stated it has 0.03% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Invesco Ltd reported 0.02% stake. Cap International Investors holds 2.81M shares. Brown Advisory Inc, a Maryland-based fund reported 304,525 shares. Balyasny Asset Management Limited Com holds 1.13 million shares. Mutual Of America Capital Management Limited Liability Company reported 0.03% stake. Susquehanna Gp Limited Liability Partnership invested in 54,851 shares. 1.53M are held by Clearbridge Invests Limited Liability Co. Neuberger Berman Gru Lc reported 16,210 shares. Spark Invest Mngmt Ltd Liability invested in 14,600 shares or 0.04% of the stock. Quantitative Investment Management Limited Liability Company has invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Pub Employees Retirement Association Of Colorado owns 6,769 shares. Royal Fincl Bank Of Canada owns 314,261 shares. Sivik Glob Health Lc owns 20,019 shares. Teacher Retirement Of Texas invested in 14,027 shares.

Among 7 analysts covering Renasant (NASDAQ:RNST), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Renasant had 21 analyst reports since October 22, 2015 according to SRatingsIntel. The firm has “Hold” rating by Jefferies given on Friday, June 9. The firm earned “Hold” rating on Monday, November 28 by Jefferies. As per Thursday, September 28, the company rating was maintained by Keefe Bruyette & Woods. Keefe Bruyette & Woods maintained Renasant Corporation (NASDAQ:RNST) rating on Friday, May 26. Keefe Bruyette & Woods has “Hold” rating and $4300 target. The firm has “Buy” rating given on Friday, February 9 by Hilliard Lyons. Hovde Group maintained the stock with “Hold” rating in Thursday, January 18 report. Sandler O’Neill upgraded Renasant Corporation (NASDAQ:RNST) on Monday, April 2 to “Buy” rating. The rating was downgraded by Raymond James to “Outperform” on Monday, September 12. The firm has “Hold” rating given on Monday, January 29 by Stephens. The firm earned “Hold” rating on Thursday, January 4 by Sandler O’Neill.

Renasant Corporation (NASDAQ:RNST) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>